IN8bio (NASDAQ:INAB) released its earnings results on Friday. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.60), MarketWatch Earnings reports.
Shares of INAB stock opened at $8.89 on Friday. IN8bio has a 52 week low of $6.10 and a 52 week high of $10.32.
A number of research firms recently weighed in on INAB. B. Riley began coverage on shares of IN8bio in a research note on Monday, August 23rd. They set a “buy” rating and a $19.00 target price on the stock. Mizuho began coverage on shares of IN8bio in a research note on Tuesday, August 24th. They set a “buy” rating and a $12.00 target price on the stock.
IN8bio Inc is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company’s principal candidate includes INB-200, which are in clinical stage. IN8bio Inc is based in New York.
See Also: What is Depreciation?
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.